Dr.ย Xichunย Hu
MD, PhD
Professor & Director, Department of Medical Oncology
corporate_fareFudan University Shanghai Cancer Center, Shanghai
Xichun Hu
MD, PhD
Prof. Xichun Hu is one of China's leading breast medical oncologists, serving as Professor and Director of the Department of Medical Oncology at Fudan University Shanghai Cancer Center in Shanghai. His clinical practice is dedicated to the diagnosis and systemic treatment of breast cancer, with a particular focus on advanced, metastatic, triple-negative, and HER2-positive breast cancer.
With a career spanning more than three decades, Prof. Hu has built a research-active practice at one of China's premier specialist cancer institutions. He has published more than 200 peer-reviewed papers on breast cancer, contributed to Chinese advanced breast cancer guidelines and Chinese Breast Cancer Society treatment guidelines, and led or participated in numerous clinical trials evaluating new anticancer agents and combination regimens. His translational research interests encompass biomarkers, angiogenesis, gene expression, epigenetic alterations, residual disease detection, and phase I drug development. He holds international academic recognition through ESMO Breast Cancer Faculty membership and professional leadership roles in Chinese oncology societies.
CancerFax can coordinate medical record review, second opinion preparation, and appointment planning for international patients seeking consultation with Prof. Hu at Fudan University Shanghai Cancer Center.
Why Consider Prof. Xichun Hu?
Prof. Xichun Hu combines senior clinical leadership with one of China's strongest individual breast cancer research records, making him a relevant choice for patients with advanced, metastatic, or treatment-resistant breast cancer.
Areas of Specialisation
Advanced breast cancer management with a research-integrated clinical approach
Prof. Hu's specialisation covers the full spectrum of breast cancer management, from systemic therapy planning in early-stage disease to complex decision-making in advanced and metastatic settings. His practice is particularly focused on molecularly guided treatment strategies, new drug development, and clinical trial participation.
Advanced & Metastatic Breast Cancer
Systemic therapy planning and management for patients with locally advanced, recurrent, or metastatic breast cancer.
- arrow_rightSequential systemic therapy planning for metastatic disease
- arrow_rightChemotherapy regimen selection based on prior treatment history and pathology
- arrow_rightBone metastasis management and supportive treatment planning
- arrow_rightChemotherapy optimisation for triple-negative metastatic disease
- arrow_rightEvaluation of immunotherapy and PARP inhibitor eligibility
- arrow_rightParticipation in clinical trials targeting triple-negative subtype
HER2-Positive Breast Cancer
Anti-HER2 treatment strategies including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates.
- arrow_rightTrastuzumab and pertuzumab-based treatment planning
- arrow_rightAntibody-drug conjugate evaluation including ARX788 and trastuzumab deruxtecan
- arrow_rightLapatinib-based and TKI regimen selection for advanced HER2-positive disease
Translational Research & New Drug Development
Phase I clinical trials and translational oncology research focused on breast cancer biomarkers and novel anticancer agents.
- arrow_rightPhase I trials of new anticancer agents
- arrow_rightBiomarker-driven patient selection for novel therapies
- arrow_rightAngiogenesis, gene expression, and residual disease research
Procedures & Treatments
Medical oncology services for breast cancer patients
Prof. Hu provides medical oncology consultation and treatment planning for breast cancer, with an emphasis on advanced and metastatic disease. His services encompass systemic therapy, clinical trial enrolment evaluation, and guideline-aligned treatment planning.
Systemic Breast Cancer Treatment
Medical OncologyChemotherapy and systemic therapy planning for early, locally advanced, and metastatic breast cancer.
Anti-HER2 & Antibody-Drug Conjugate Therapy
Targeted TherapyAnti-HER2 targeted treatment planning including novel antibody-drug conjugate evaluation.
Clinical Trial Enrolment Assessment
Complex DiseaseEvaluation of eligibility for breast cancer clinical trials at Fudan University Shanghai Cancer Center.
Second Opinion & Case Review
Second OpinionIndependent expert review of breast cancer pathology, molecular profiling, and treatment plans.
Research & Publications
Breast cancer research leadership with a substantial international publication record
Prof. Hu has published more than 200 peer-reviewed papers on breast cancer and contributed to 9 edited monographs. His research spans advanced breast cancer management, HER2-positive disease, triple-negative breast cancer, clinical drug development, and translational oncology.
Prof. Hu leads active clinical trials at Fudan University Shanghai Cancer Center. CancerFax can assist eligible patients in assessing trial participation options for metastatic and triple-negative breast cancer.
Education & Training
Prof. Hu completed his medical and oncology training across leading institutions in China and Hong Kong, followed by international fellowship exposure at Mayo Clinic.
Clinical Experience
Prof. Hu has spent his career at Fudan University Shanghai Cancer Center, where he has served as both the clinical director and academic leader of the Department of Medical Oncology, building one of China's most research-active breast cancer practices.
Languages & International
Prof. Hu's consultations are conducted in Mandarin Chinese. For international patients, CancerFax coordinates professional medical interpreter support.
CancerFax coordinates professional medical interpreters for international patients consulting with Prof. Hu, covering English and other major languages.
CancerFax provides professional medical interpreter support for English, Arabic, Russian, and other languages to ensure clear communication throughout the consultation process.
How CancerFax Helps You Access Dr. Xichun Hu
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Xichun Hu's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Xichun Hu's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Xichun Hu before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Xichun Hu's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Xichun Hu's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Xichun Hu's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Xichun Hu
Prof. Hu specialises in medical oncology with a primary focus on breast cancer, including advanced breast cancer, metastatic breast cancer, triple-negative breast cancer, and HER2-positive breast cancer. His clinical and research work covers the full spectrum of breast cancer subtypes requiring systemic treatment.
Prof. Hu is based at Fudan University Shanghai Cancer Center in Shanghai, China, where he serves as Professor and Director of the Department of Medical Oncology. The hospital is one of China's leading specialist cancer institutions.
CancerFax can coordinate medical record review and consultation support for international patients seeking an opinion from Prof. Hu, subject to hospital availability and case acceptance. Submit your reports through CancerFax and the team will handle case preparation and next steps.
A second opinion request can be submitted through CancerFax with the patient's pathology reports, receptor status results, imaging, treatment history, and molecular profiling where available. The CancerFax team prepares the case for review and coordinates the consultation format with the hospital.
Yes. Fudan University Shanghai Cancer Center lists multiple ongoing clinical trials associated with Prof. Hu, including trials in metastatic breast cancer and triple-negative metastatic breast cancer. CancerFax can assist eligible patients in assessing whether trial participation may be appropriate for their case.
Prof. Hu holds an MD and a PhD. He completed his undergraduate medical training at Suzhou Medical College, graduate oncology study at Shanghai Medical University, and his PhD at The University of Hong Kong. He also completed an international visiting fellowship at Mayo Clinic, Rochester, in 2007.
Connect with Xichun Hu Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.